Evidence map›Paper›PMID 39443544›Full record

ArticleScientific reports2024

Profiling of urinary extracellular vesicle protein signatures from patients with cribriform and intraductal prostate carcinoma in a cross-sectional study.

Rui Bernardino, Ana Sofia Carvalho, Michael J Hall, Liliana Alves, Ricardo Leão, Rashid Sayyid, Hermínia Pereira, Hans Christian Beck, Luís Campos Pinheiro, Rui Henrique and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Role of Fetuin-A in Tumor Cell Growth, Prognosis, and Dissemination.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rui BernardinoComputational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisboa, Portugal. ruimmbernardino@gmail.com.
Ana Sofia CarvalhoComputational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisboa, Portugal. ana.carvalho@nms.unl.pt.
Michael J HallComputational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisboa, Portugal.
Liliana AlvesComputational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisboa, Portugal.
Ricardo LeãoCuf Hospitais, Lisbon, Portugal.
Rashid SayyidDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Hermínia PereiraDepartment of Pathology, Centro Hospitalar E Universitário Lisboa Central, Lisbon, Portugal.
Hans Christian BeckCentre for Clinical Proteomics, Department of Clinical Biochemistry, Odense University Hospital, 5000, Odense, Denmark.
Luís Campos PinheiroDepartment of Urology, Centro Hospitalar e Universitário Lisboa Central, Lisbon, Portugal.
Rui HenriqueDepartment of Pathology and Cancer Biology and Epigenetics Group - Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Neil FleshnerDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Rune MatthiesenComputational and Experimental Biology Group, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisboa, Portugal. rune.matthiesen@nms.unl.pt.

Funding

COST Action "PROTEOCURE CA20113388Fundação para a Ciência e a Tecnologia 10.54499/CEECIND/03906/2017/CP1421/CT0004Fundação para a Ciência e a Tecnologia 10.54499/DL57/2016/CP1457/CT0013Fundação para a Ciência e a Tecnologia 2022.13386.BDHorizon2020 GA, EVCA n° 101079264iNOVA4Health UIDB/04462/2020 and UIDP/04462/2020Portuguese Foundation for Science and Technology PTDC/BTM-TEC/1746/2021
6 · The paper itself

Abstract

Prognostic tests and treatment approaches for optimized clinical care of prostatic neoplasms are an unmet need. Prostate cancer (PCa) and derived extracellular vesicles (EVs) proteome changes occur during initiation and progression of the disease. PCa tissue proteome has been previously characterized, but screening of tissue samples constitutes an invasive procedure. Consequently, we focused this study on liquid biopsies, such as urine samples. More specifically, urinary small extracellular vesicle and particles proteome profiles of 100 subjects were analyzed using liquid chromatography coupled to high-resolution mass spectrometry (LC-MS/MS). We identified 171 proteins that were differentially expressed between intraductal prostate cancer/cribriform (IDC/Crib) and non-IDC/non-Crib after correction for multiple testing. However, the strong correlation between IDC/Crib and Gleason Grade complicates the disentanglement of the underlying factors driving this association. Nevertheless, even after accounting for multiple testing and adjusting for ISUP (International Society of Urological Pathology) grading, two proteins continued to exhibit significant differential expression between IDC/Crib and non-IDC/non-Crib. Functional enrichment analysis based on cancer hallmark proteins disclosed a clear pattern of androgen response down-regulation in urinary EVs from IDC/Crib compared to non-IDC/non-Crib. Interestingly, proteome differences between IDC and cribriform were more subtle, suggesting high proteome heterogeneity. Overall, the urinary EV proteome reflected partly the prostate pathology.

Indexed as

Extracellular VesiclesProstatic NeoplasmsAgedBiomarkers, TumorChromatography, LiquidCross-Sectional StudiesHumansMaleMiddle AgedNeoplasm GradingProteomeProteomicsTandem Mass SpectrometryBiomarkers, TumorProteomeCribriformIntraductal prostate carcinomaLiquid chromatography mass spectrometryProteomicsUrinary extracellular vesicles and particles

Identifiers

PMID39443544
PMCPMC11500006

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.